Subdermal Contraceptive Implants

Global Subdermal Contraceptive Implants Market to Reach US$1.6 Billion by 2030

The global market for Subdermal Contraceptive Implants estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Etonogestrel Implant, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Levonorgestrel Implant segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 10.8% CAGR

The Subdermal Contraceptive Implants market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$337.7 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Subdermal Contraceptive Implants Market – Key Trends & Drivers Summarized

Why Are Subdermal Implants Gaining Favor Over Traditional Contraceptives?

Subdermal contraceptive implants are witnessing a notable surge in global adoption, largely due to the growing preference for long-acting reversible contraceptives (LARCs) among women of reproductive age. Unlike daily oral contraceptives or short-term methods like patches and injections, subdermal implants offer protection for three to five years with a single insertion, significantly reducing the risk of user error and increasing overall efficacy. The market is benefitting from increased awareness and education about reproductive rights and contraception options, particularly in developing regions where access to healthcare is improving. Furthermore, public health initiatives by organizations such as the World Health Organization (WHO), UNFPA, and USAID are actively promoting the use of implants in regions with high fertility rates and limited access to contraceptive resources. Compared to intrauterine devices (IUDs), subdermal implants are less invasive and do not require uterine placement, making them a preferred option for women who may not have given birth. The minimal maintenance, discreet nature, and reversible function of implants are reshaping how contraception is viewed, shifting the narrative toward convenience, autonomy, and long-term planning. As a result, these devices are not only finding favor in urban, educated populations but also penetrating rural and underserved areas via government and NGO-supported programs.

How Are Healthcare Policies and Global Campaigns Accelerating Adoption?

Government healthcare policies and international campaigns are playing a central role in accelerating the adoption of subdermal contraceptive implants, especially in regions with unmet needs for family planning. In low- and middle-income countries (LMICs), the push toward universal access to reproductive healthcare under frameworks like the Sustainable Development Goals (SDGs) has spurred large-scale procurement and subsidized distribution of contraceptive implants. Initiatives such as the FP2030 partnership and global donor alliances have secured favorable pricing agreements with manufacturers, ensuring implants are affordable or free to millions of women worldwide. National governments, particularly in Sub-Saharan Africa and Southeast Asia, are integrating subdermal implants into public health programs and providing training for community health workers to increase outreach and trust. Meanwhile, in developed countries, policy shifts around women`s health, gender equity, and reproductive autonomy have led to insurance coverage for LARCs, boosting their uptake among teenagers and young adults. School-based and clinic-based awareness campaigns, alongside expanding access via telehealth and pharmacy-based models, are ensuring that information and services reach broader populations. These coordinated policy and advocacy efforts are reducing stigma, improving access, and ensuring that women can make informed choices about their reproductive health—factors that are directly driving growth in the subdermal contraceptive implant market.

Are Technological Innovations Enhancing Device Design and Acceptance?

Yes, technological innovations in implant design and insertion methods are making subdermal contraceptive implants more appealing, safer, and easier to use for both healthcare providers and patients. The market is seeing a shift toward next-generation implants with thinner, more flexible rods that are easier to insert and remove with minimal discomfort. Advancements in bioresorbable materials and hormone release mechanisms are allowing for more consistent and controlled delivery of active agents like etonogestrel, thereby improving efficacy and reducing side effects. Device manufacturers are also developing smart insertion kits that reduce procedural time and complexity, further encouraging healthcare providers to offer the method. Some research efforts are focused on digital or trackable implants, incorporating microchips or radio-frequency identification (RFID) tags that can store dosing information and facilitate patient follow-up. Additionally, there’s an increased emphasis on culturally sensitive packaging and instruction materials, improving acceptance in diverse sociocultural contexts. As removal continues to be a concern in some regions, efforts are being made to ensure training programs focus equally on insertion and safe, timely removal. All these technological strides are making the devices more user-centric, thereby enhancing patient satisfaction and expanding market reach across different healthcare ecosystems.

What’s Behind the Rising Demand for These Implants Around the World?

The growth in the subdermal contraceptive implants market is driven by several factors rooted in reproductive health trends, healthcare access, demographic shifts, and medical innovation. The rising global demand for effective, low-maintenance contraception is a major driver, particularly among women seeking autonomy in family planning without daily adherence challenges. Younger populations in both urban and rural areas are showing increased interest in discreet, long-term contraceptive solutions, and implants fit that profile well. Growing awareness of the health and economic benefits of delayed or spaced pregnancies, supported by data and educational campaigns, is influencing more women to choose long-acting methods. Furthermore, the proliferation of government and NGO-supported reproductive health programs is making these implants more accessible and affordable across a wider range of socioeconomic groups. From a healthcare provider standpoint, implants are now favored due to simplified administration protocols, shorter procedure times, and fewer follow-up requirements compared to alternatives. Technological refinement in the devices themselves—such as longer duration, improved hormone delivery, and easier removability—is reinforcing consumer trust. Regulatory bodies worldwide are also fast-tracking approval and adoption of new models, recognizing their public health value. Lastly, shifting cultural attitudes toward family planning and increased female participation in education and the workforce are reinforcing the importance of reproductive autonomy, making subdermal implants a compelling solution in modern contraceptive care.

SCOPE OF STUDY:

The report analyzes the Subdermal Contraceptive Implants market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Etonogestrel Implant, Levonorgestrel Implant); Distribution Channel (Hospital, Gynecology Clinics, Community Health Care Centers, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Allergan plc
• Baxter International Inc.
• Bayer AG
• Bayer Schering Pharma
• Conceptus Inc.
• Contraline, Inc.
• DKT International
• DKT WomanCare
• Eli Lilly and Company
• FHI 360
• Gerresheimer AG
• HRA Pharma
• Karex Industries
• KESSEL medintim GmbH
• Leiras Oy
• Mayer Laboratories
• Merck & Co., Inc.
• Novartis AG
• Organon
• Pfizer Inc.
• Population Council
• Reckitt Benckiser Group plc
• Sandoz International GmbH
• Schott AG
• Shanghai Dahua Pharmaceutical Co., Ltd.
• SMB Corporation
• Teva Pharmaceutical Industries Ltd.
• The Female Health Company
• Theramex
• Wyeth Pharmaceuticals

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.